Global Formulation Development Outsourcing Market Research Report—Forecast till 2027

Table of Contents

TABLE OF CONTENT 1 EXECUTIVE SUMMARY 1.1 MARKET SYNOPSIS 16 2 MARKET INTRODUCTION 2.1 SCOPE OF THE STUDY 17 2.2 RESEARCH OBJECTIVE 17 2.3 LIST OF ASSUMPTIONS & LIMITATIONS 17 3 RESEARCH METHODOLOGY 3.1 OVERVIEW 19 3.2 DATA MINING 19 3.3 SECONDARY RESEARCH 20 3.4 PRIMARY RESEARCH 21 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 21 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 22 3.5 FORECASTING TECHNIQUES 23 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 24 3.6.1 BOTTOM-UP APPROACH 24 3.6.2 TOP-DOWN APPROACH 25 3.7 DATA TRIANGULATION 25 3.8 VALIDATION 25 4 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES 4.1 INTRODUCTION 26 4.2 PREFORMULATION SERVICES 27 4.2.1 FORMULATION DISCOVERY 28 4.2.2 PRECLINICAL SERVICES 28 4.2.3 ANALYTICAL SERVICES 29 4.3 FORMULATION OPTIMIZATION 29 4.3.1 PHASE I 30 4.3.2 PHASE II 30 4.3.3 PHASE III 31 4.3.4 PHASE IV 31 5 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM 5.1 INTRODUCTION 32 5.2 INJECTABLE 34 5.3 ORAL 34 5.4 TOPICAL 35 5.5 INHALED 35 5.6 OTHERS 36 6 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION 6.1 INTRODUCTION 37 6.2 ONCOLOGY 39 6.3 GENETIC DISORDERS 40 6.4 NEUROLOGY 40 6.5 INFECTIOUS DISEASES 41 6.6 RESPIRATORY 41 6.7 CARDIOVASCULAR 42 6.8 OTHERS 42 7 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER 7.1 INTRODUCTION 43 7.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 44 7.3 GOVERNMENT & ACADEMIC INSTITUTES 44 8 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY REGION 8.1 INTRODUCTION 45 8.2 AMERICAS 46 8.2.1 NORTH AMERICA 48 8.2.1.1 US 51 8.2.1.2 CANADA 53 8.2.2 LATIN AMERICA 55 8.3 EUROPE 58 8.3.1 WESTERN EUROPE 61 8.3.1.1 GERMANY 63 8.3.1.2 FRANCE 65 8.3.1.3 UK 67 8.3.1.4 ITALY 69 8.3.1.5 SPAIN 71 8.3.1.6 REST OF WESTERN EUROPE 73 8.3.2 EASTERN EUROPE 75 8.4 ASIA-PACIFIC 78 8.4.1 JAPAN 80 8.4.2 CHINA 82 8.4.3 INDIA 84 8.4.4 AUSTRALIA 86 8.4.5 SOUTH KOREA 88 8.4.6 REST OF ASIA-PACIFIC 90 8.5 MIDDLE EAST & AFRICA 93 8.5.1 MIDDLE EAST 95 8.5.2 AFRICA 97 9 COMPETITIVE LANDSCAPE 9.1 OVERVIEW 100 9.2 MARKET SHARE ANALYSIS 100 9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL FORMULATION DEVELOPMENT OUTSOURCING SERVICES MARKET 101 9.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL FORMULATION DEVELOPMENT OUTSOURCING SERVICES MARKET 102 9.5 KEY DEVELOPMENT ANALYSIS 102 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 103 9.6.1 ACQUISITION ACTIVITIES 103 9.6.2 EXPANSION 104 9.6.3 FINANCIAL MATRIX 104 9.6.4 R&D EXPENDITURE 104 10 COMPANY ANALYSIS 10.1 CHARLES RIVER LABORATORIES 105 10.2 AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED 106 10.3 CATALENT, INC. 108 10.4 LABORATORY CORPORATION OF AMERICA 109 10.5 SYNGENE INTERNATIONAL LTD. 110 10.6 IRISYS, LLC 111 10.7 INTERTEK 112 10.8 PIRAMAL ENTERPRISES LTD. 113 10.9 QUOTIENT SCIENCES 114 10.10 PATHEON (THERMO FISHER SCIENTIFIC) 115 10.11 EMERGENT BIOSOLUTIONS INC. 116 10.12 LONZA 117 10.13 PCI 118 10.14 DR. REDDY’S LABORATORIES LTD. 118 11 COMPANY PROFILES 11.1 AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED 119 11.1.1 COMPANY OVERVIEW 119 11.1.2 FINANCIAL OVERVIEW 119 11.1.3 PRODUCTS/SERVICES OFFERED 119 11.1.4 KEY DEVELOPMENTS 121 11.1.5 SWOT ANALYSIS 122 11.1.6 KEY STRATEGIES 122 11.2 IRISYS, INC. 123 11.2.1 COMPANY OVERVIEW 123 11.2.2 FINANCIAL OVERVIEW 123 11.2.3 PRODUCTS/SERVICES OFFERED 123 11.2.4 KEY DEVELOPMENTS 124 11.2.5 SWOT ANALYSIS 125 11.2.6 KEY STRATEGIES 125 11.3 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 126 11.3.1 COMPANY OVERVIEW 126 11.3.2 FINANCIAL OVERVIEW 126 11.3.3 PRODUCTS OFFERED 127 11.3.4 KEY DEVELOPMENTS 128 11.3.5 SWOT ANALYSIS 128 11.3.6 KEY STRATEGIES 128 11.4 INTERTEK GROUP PLC 129 11.4.1 COMPANY OVERVIEW 129 11.4.2 FINANCIAL OVERVIEW 129 11.4.3 PRODUCTS/SERVICES OFFERED 130 11.4.4 KEY DEVELOPMENTS 131 11.4.5 SWOT ANALYSIS 131 11.4.6 KEY STRATEGIES 131 11.5 CATALENT, INC. 132 11.5.1 COMPANY OVERVIEW 132 11.5.2 FINANCIAL OVERVIEW 132 11.5.1 PRODUCTS/SERVICES OFFERED 133 11.5.2 KEY DEVELOPMENTS 134 11.5.3 SWOT ANALYSIS 134 11.5.4 KEY STRATEGIES 135 11.6 SYGENE INTERNATIONAL LIMITED 136 11.6.1 COMPANY OVERVIEW 136 11.6.2 FINANCIAL OVERVIEW 136 11.6.3 PRODUCTS/SERVICES OFFERED 137 11.6.4 KEY DEVELOPMENTS 138 11.6.5 SWOT ANALYSIS 139 11.6.6 KEY STRATEGIES 139 11.7 LABORATORY CORPORATION OF AMERICA HOLDINGS 140 11.7.1 COMPANY OVERVIEW 140 11.7.2 FINANCIAL OVERVIEW 140 11.7.3 PRODUCTS/SERVICES OFFERED 141 11.7.4 KEY DEVELOPMENTS 141 11.7.5 SWOT ANALYSIS 142 11.7.6 KEY STRATEGIES 142 11.8 PATHEON (THERMO FISHER SCIENTIFIC) 143 11.8.1 COMPANY OVERVIEW 143 11.8.2 FINANCIAL OVERVIEW 143 11.8.3 PRODUCTS/SERVICES OFFERED 144 11.8.4 KEY DEVELOPMENTS 145 11.8.5 SWOT ANALYSIS 145 11.8.6 KEY STRATEGIES 146 11.9 QUOTIENT SCIENCES 147 11.9.1 COMPANY OVERVIEW 147 11.9.2 FINANCIAL OVERVIEW 147 11.9.3 PRODUCTS/SERVICES OFFERED 147 11.9.4 KEY DEVELOPMENTS 148 11.9.5 SWOT ANALYSIS 148 11.9.6 KEY STRATEGIES 148 11.10 EMERGENT BISOLUTIONS INC. 149 11.10.1 COMPANY OVERVIEW 149 11.10.2 FINANCIAL OVERVIEW 149 11.10.3 PRODUCTS/SERVICES OFFERED 149 11.10.4 KEY DEVELOPMENTS 150 11.10.5 SWOT ANALYSIS 150 11.10.6 KEY STRATEGIES 150 12 APPENDIX 12.1 REFERENCES 151 12.2 RELATED REPORTS 152